The current approach of morbidity control of schistosomiasis, a helminth disease of poverty
with considerable public health and socioeconomic impact, is based on preventive …

Schistosomiasis, a neglected tropical disease provoked by infection with parasitic blood
flukes of the genus Schistosoma, affects almost 240 million people worldwide, and more …

No major changes have occurred during the past 20 years regarding the therapeutic tools
available to the clinician for the treatment of schistosomiasis. If anything, the two drugs …

Praziquantel became available for the treatment of schistosomiasis and other trematode-
inflicted diseases in the 1970s. It was revolutionary because it could be administered orally …

Despite the limited reports of praziquantel resistance, the relative success of chemotherapy-
based control programmes for schistosomiasis has prompted overdue efforts to expand the …

With just one drug used for individual patient management and community-based morbidity
control, the treatment, control, and eventual elimination of schistosomiasis is vulnerable …

Schistosomiasis is a chronic parasitic disease in tropical and subtropical regions and is
associated with a variety of clinical syndromes that may lead to severe morbidity. Over the …

Schistosomiasis is a major disease of public health importance in humans occurring in over
70 countries of the tropics and sub-tropics. In this chapter, the history of the control of …

Schistosomiasis, or bilharzias, is a neglected disease that remains a considerable public
health problem in tropical and subtropical regions. This parasitic disease is the most …

Chemotherapy is widely acknowledged as the most important, rapid and cost-effective
method of reducing morbidity due to schistosome infections. The discovery of praziquantel in …